Dr. Klein on Challenges With Active Surveillance in Prostate Cancer

Video

Eric A. Klein, MD, discusses challenges with active surveillance in prostate cancer.

Eric A. Klein, MD, chairman of the Glickman Urological & Kidney Institute and staff member in the Taussig Cancer Institute at Cleveland Clinic, discusses challenges with active surveillance in prostate cancer.

When looking at a study conducted at John Hopkins, one of the leaders in recommending active surveillance to patients a few decades ago, investigators followed a group of 1000 patients for a total of 15 years. Notably, the patients did very well and very few deaths were reported, Klein adds.

However, patients had to get a biopsy every year, for all 15 years. Biopsies are not easy for patients, Klein explains. Moreover, several risks are associated with biopsies such as bacteremia and sepsis, and in the past, even occasional deaths have been reported, Klein concludes.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD